Market Analysis Report Point of Care Diagnostic Devices Market Report 201 | Page 2

The report begins from overview of Industry Chain structure, and describes industry environment, then
analyses market size and forecast of Point of Care Diagnostic Devices Market by product, region and
application, in addition, this report introduces market competition situation among the vendors and
company profile, besides, market price analysis and value chain features are covered in this report. The
scope of the report includes a detailed study of Point of Care Diagnostic Devices Market with the
reasons given for variations in the growth of the industry in certain regions.
Point-of-care (POC) diagnosis mainly involves various testing of patients' samples at the point of care for
facilitating rapid treatment plan. Such diagnostic procedure allows early disease detection and can
greatly impact the disease treatment. Several advanced technologies used in point-of-care diagnostics
include agglutination assays, lateral flow, solid phase, and biosensors, which are all unique for certain
conditions.
Point of Care Diagnostic Devices Market Covers the Table of Contents With Segments, Key Players And
Region. Based on Product Type, Point of Care Diagnostic Devices Market is sub segmented into Blood
Glucose Testing, Infectious Diseases Testing, Cardiac Markers Testing, Coagulation Testing, Pregnancy
and Fertility Testing. On the Basis of Application, Market is sub segmented into Clinics, Hospitals,
Laboratory.
Major Players profiled in the Point of Care Diagnostic Devices Market report incorporate: Alere, Roche,
Abbott Laboratories, Johnson & Johnson, Siemens Healthcare, Danaher, Bayer Healthcare, Beckman
Coulter, Nipro Diagnostics, Bio-Rad Laboratories, Nova Biomedical, BioMerieux, Quidel, Helena
Laboratories, OraSure Technologies, Accriva
Top Industry news for Point of Care Diagnostic Devices Market
Abbott Laboratories
Abbott today announced that its Afinion™ HbA1c Dx assay is now available for use on the Afinion 2
Analyzer, as well as the Afinion AS100 Analyzer. The Afinion HbA1c Dx assay is the first and only rapid
point-of-care test cleared by the U.S. Food and Drug Administration (FDA) to aid healthcare
professionals in the diagnosis of diabetes and the assessment of patients' risk of developing the
condition.
The Afinion HbA1c Dx meets FDA's stringent requirements for performance testing for diagnostic use
claims. The test delivers accurate and precise1,2 glycated hemoglobin (HbA1c) results in only three
minutes, enabling clinicians to diagnose patients and help them formulate individualized care plans
during a single doctor's office visit. The Afinion HbA1c Dx assay (approved for monitoring and diagnosis)
complements the Afinion HbA1c assay (approved for monitoring only), the number one point-of-care
HbA1c test in the U.S. for monitoring long-term glycemic control in diabetes.3
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/167470 .